MSC and HSC Coinfusion in Mismatched Minitransplants
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The present project aims at evaluating the capacity of MSC to improve one-year overall survival of patients transplanted with HLA-mismatched PBSC from related or unrelated donors after non-myeloablative conditioning.
Co-infusion of MSC has been shown to facilitate engraftment of hematopoietic stem cell (HSC) in an immunodeficient mouse model. In addition, it has been shown that infusion of third party MSC in HSC transplantation could be successfully used as treatment for grade II-IV steroid-refractory acute graft versus host disease.
One hundred and twenty patients with HLA-mismatched donors will be included over 6 years at multiple centers across Belgium through the transplant committee of the Belgian Hematological Society. The conditioning regimen will consist of fludarabine and 2 Gy TBI, followed by the infusion of donor HSC. Patients will be randomized 1/1 in double-blind fashion to receive or not MSC (1.5-.3.0 x106/kg) from third-party (either haploidentical family members or unrelated volunteer) donors on day 0. Postgrafting immunosuppression will combine tacrolimus and MMF. Except for the collection, expansion and infusion of MSC, the clinical management of the patient will not differ from that of routine NM-HCT.
| Condition | Intervention | Phase |
|---|---|---|
|
Leukemia, Myeloid, Acute Leukemia, Lymphoblastic, Acute Leukemia, Myelocytic, Chronic Myeloproliferative Disorders Myelodysplastic Syndromes Multiple Myeloma Leukemia, Lymphocytic, Chronic Hodgkin's Disease Lymphoma, Non-Hodgkin |
Biological: Mesenchymal stem cells Other: Isotonic solution |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver) Primary Purpose: Treatment |
| Official Title: | Co-transplantation of Mesenchymal Stem Cells and HLA-mismatched Allogeneic Hematopoietic Cells After Nonmyeloablative Conditioning: a Phase II Randomized Double-blind Study |
- One-year overall survival in the 2 arms. [ Time Frame: One year ] [ Designated as safety issue: No ]
- Incidence of grade II-IV and grade III-IV acute GVDH [ Time Frame: 100 days ] [ Designated as safety issue: No ]
- Number of absolute donor T cells after HCT in each arm [ Time Frame: 28 ] [ Designated as safety issue: No ]
- Cumulative incidence of non-relapse mortality [ Time Frame: 100, 365 and 730 days ] [ Designated as safety issue: Yes ]
- Incidence of extensive chronic GVHD in each arm [ Time Frame: 365 days ] [ Designated as safety issue: No ]
- Incidence of graft rejection in each arm. [ Time Frame: 365 days ] [ Designated as safety issue: No ]
- Quality and timing of immunologic reconstitution in each arm. [ Time Frame: 100, 365 and 730 days ] [ Designated as safety issue: No ]
- Detection of MSC from donor origin in recipient marrow after HCT in patients given MSC [ Time Frame: 40 days ] [ Designated as safety issue: No ]
- Proportion of patients with measurable disease at HCT who achieve a complete response in each arm. [ Time Frame: 100, 365 and 730 days ] [ Designated as safety issue: Yes ]
- Cumulative incidence of relapse [ Time Frame: 365 and 730 days ] [ Designated as safety issue: Yes ]
- Incidence of progression-free survival [ Time Frame: 365 and 730 days ] [ Designated as safety issue: No ]
- Incidence of infections [ Time Frame: 100 days ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 120 |
| Study Start Date: | July 2010 |
| Estimated Study Completion Date: | July 2018 |
| Estimated Primary Completion Date: | July 2016 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Mensenchymal Stem Cells
Efficacy of MSC infusion on one-year overall survival of patients transplanted with HLA-mismatched PBSC. Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2 Gy total body irradiation. MSC cells (1,5-3,0 x 10E6 MSC/Kg BW) will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor. |
Biological: Mesenchymal stem cells
Mesenchymal stem cell injection
|
|
Placebo Comparator: Placebo
Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2Gy total body irradiation. Isotonic solution will be injected will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor. |
Other: Isotonic solution
Isotonic solution injection
|
Eligibility| Ages Eligible for Study: | up to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Theoretical indication for a standard allo-transplant, but not feasible because: Age > 55 yrs. Unacceptable end organ performance. Patient's refusal.
- Indication for a standard auto-transplant: perform mini-allotransplantation 2-6 months after standard autotransplant.
- Male or female; fertile female patients must use a reliable contraception method
- Age ≤ 75 year old
- Informed consent given by patient or his/her guardian if of minor age.
One or two HLA mismatches with PBSC:
- One antigenic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1
- Two allelic mismatches at HLA-A or -B or -C or -DRB1 or -DQB1
- One antigenic mismatch: 1 allelic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1.
- One antigenic mismatch at -DQB1 and one other antigenic mismatch at HLA-A or -B or -C or -DRB1
- Patients with one single allelic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1 can also be included in the protocol.
Hematological malignancies confirmed histologically and not rapidly progressing:
- AML in complete remission
- ALL in complete remission
- CML unresponsive/intolerant to Imatinib but not in blast crisis
- Other myeloproliferative disorders not in blast crisis and not with extensive myelofibrosis
- MDS with <5% blasts
- Multiple myeloma not rapidly progressing
- CLL
- Non-Hodgkin's lymphoma (aggressive NHL should be chemosensitive)
- Hodgkin's disease
Exclusion Criteria:
- Any condition not fulfilling inclusion criteria
- HIV positive
Terminal organ failure, except for renal failure (dialysis acceptable)
- Cardiac: Symptomatic coronary artery disease or other cardiac failure requiring therapy; ejection fraction <35%; uncontrolled arrhythmia; uncontrolled hypertension
- Pulmonary: DLCO < 35% and/or receiving supplementary continuous oxygen
- Hepatic: Fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3 mg/dL, and symptomatic biliary disease
- Uncontrolled infection, arrhythmia or hypertension
- Previous radiation therapy precluding the use of 2 Gy TBI
- 10/10 HLA-A, -B, -C, DRB1 and DQBI allele-matched donor fit to/willing to donate PBSC.
Contacts and Locations| Contact: Yves Beguin, MD, PhD | 00/32/4 366 7201 | yves.beguin@chu.ulg.ac.be |
| Contact: Frédéric Baron, MD, PhD | 00/32/4 366 7201 | F.Baron@ulg.ac.be |
| Belgium | |
| UZA | Recruiting |
| Edeghem, Antwerpen, Belgium, 2650 | |
| Contact: Wilfried Schroyens, MD, PhD 32 382 204111 wilfried.schroyens@uza.be | |
| Principal Investigator: Wilfried Schroyens, MD, PhD | |
| St-Luc UCL | Recruiting |
| Brussels, Brabant, Belgium, 1200 | |
| Contact: Augustin Ferrant, MD, PhD 32 27641880 ferrant@sang.ul.ac.be | |
| Principal Investigator: Augustin Ferrant, MD, PhD | |
| AZ Gasthuisberg Leuven | Recruiting |
| Leuven, Flamish Brabant, Belgium, 3000 | |
| Contact: Johan Maertens, MD 32- 16 33 22 11 johan.maertens@uz.kuleuven.ac.be | |
| Principal Investigator: Johan Maertens, MD | |
| UZ Gent | Recruiting |
| Gent, Flanders Ost, Belgium, 9000 | |
| Contact: Lucien Noens, MD, PhD 32(09) 332 21 31 Lucien.Noens@Ugent.be | |
| Principal Investigator: Lucien Noens, MD, PhD | |
| Sub-Investigator: Tessa Kerre, MD, PhD | |
| AZ St-Jan | Recruiting |
| Brugge, Flanders West, Belgium, 8000 | |
| Contact: Dominik Selleslag, MD 00/32/50 453060 dominik.selleslag@azbrugge.be | |
| Principal Investigator: Dominik Selleslag, MD | |
| Cliniques Universitaires Mont-Godinne | Recruiting |
| Yvoir, Namur, Belgium, 5530 | |
| Contact: Carlos Graux, MD 32(081)423831 carlos.graux@uclouvain.be | |
| Contact: Chantal Doyen, MD 32(081)423831 chantal.doyen@sang.ucl.ac.be | |
| Principal Investigator: Chantal Doyen, MD, PhD | |
| Sub-Investigator: Carlos Graux, MD, PhD | |
| Hôpital Stuyvenberg | Recruiting |
| Antwerpen, Belgium, 2060 | |
| Contact: Pierre Zachée, MD, PhD 32(03)2177111 pierre.zachee@zna.be | |
| Principal Investigator: Pierre Zachée, MD, PhD | |
| Bordet Institute | Recruiting |
| Brussels, Belgium, 1000 | |
| Contact: Philippe Lewalle, MD, PhD 00/32/2 5417208 plewalle@ulb.ac.be | |
| Contact: Dominique Bron, MD, PhD 00/32/ 2 5417208 bron@ulb.ac.be | |
| Principal Investigator: Philippe Lewalle, MD, PhD | |
| Sub-Investigator: Dominique Bron, MD, PhD | |
| Vrije Universiteit Brussel | Recruiting |
| Brussels, Belgium, 1050 | |
| Contact: Rik Schots, MD 00/32/2 4763105 Rik.Schots@uzbrussel.be | |
| Principal Investigator: Rik Schots, MD | |
| CHU-ULg | Recruiting |
| Liège, Belgium, 4000 | |
| Contact: Yves Beguin, MD, PhD 00/32/4 3667201 yves.beguin@chu.ulg.ac.be | |
| Contact: Frédéric Baron, MD, PhD 00/32/4 3667201 F.Baron@chu.ulg.ac.be | |
| Principal Investigator: Yves Beguin, MD, PhD | |
| Sub-Investigator: Frédéric Baron, MD, PhD | |
| Sub-Investigator: Chantal Lechanteur, PhD | |
| Sub-Investigator: Etienne Baudoux, MD | |
| Sub-Investigator: Evelyne Willems, MD | |
| Principal Investigator: | Yves Beguin, MD, PhD | CHU-ULg |
| Study Chair: | Frédéric Baron, MD, PhD | CHU-ULg |
| Principal Investigator: | Evelyne Willems, MD | CHU-ULg |
| Principal Investigator: | Dominik Selleslag, MD, PhD | AZ Brugge |
| Principal Investigator: | Pierre Zachée, MD, PhD | ZNA Antwerpen |
| Principal Investigator: | Philippe Lewalle, MD, PhD | Bordet Institute, Brussels |
| Principal Investigator: | Dominique Bron, MD, PhD | Bordet Institute, Brussels |
| Principal Investigator: | Wilfried Schroyens, MD, PhD | UZA Antwerpen |
| Principal Investigator: | Chantal Lechanteur, PhD | CHU-ULg |
| Principal Investigator: | Etienne Baudoux, MD | CHU-ULg |
| Principal Investigator: | Johan Maertens, MD | KUL, Leuven |
| Principal Investigator: | Rik Schots, MD, PhD | AZ VUB, Brussels |
| Principal Investigator: | Augustin Ferrant, MD, PhD | UCL St. LUC, Brussels |
| Principal Investigator: | Lucien Noens, MD, PhD | UZG Gent |
| Principal Investigator: | Chantal Doyen, MD, PhD | Cliiques Universitaire Mont-Godinne, Yvoir |
| Principal Investigator: | Tessa Kerre, MD, PhD | UZA, Antwerpen |
| Principal Investigator: | Carlos Graux, MD, PhD | Cliniques Universitaires, Mont-Godinne |
More Information
No publications provided
| Responsible Party: | Yves Beguin, Prof, University Hospital of Liege |
| ClinicalTrials.gov Identifier: | NCT01045382 History of Changes |
| Other Study ID Numbers: | TJB0909 |
| Study First Received: | January 8, 2010 |
| Last Updated: | January 17, 2013 |
| Health Authority: | Belgium: Federal Agency for Medicinal Products and Health Products |
Keywords provided by University Hospital of Liege:
|
HSC transplantation HLA-mismatched Mesenchymal stem cells GVHD co-infusion |
Additional relevant MeSH terms:
|
Hodgkin Disease Leukemia Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Lymphoid Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Myeloid, Acute Leukemia, Myeloid Leukemia, Myelogenous, Chronic, BCR-ABL Positive Lymphoma Lymphoma, Non-Hodgkin Multiple Myeloma Neoplasms, Plasma Cell Myelodysplastic Syndromes Preleukemia Myeloproliferative Disorders |
Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Leukemia, B-Cell Bone Marrow Diseases Hematologic Diseases Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hemorrhagic Disorders |
ClinicalTrials.gov processed this record on June 18, 2013